Surgery for pre- and minimally invasive lung adenocarcinoma
- PMID: 33485660
- DOI: 10.1016/j.jtcvs.2020.11.151
Surgery for pre- and minimally invasive lung adenocarcinoma
Abstract
Objective: Adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) are the pre- and minimally invasive forms of lung adenocarcinoma. We aimed to investigate safety results and survival outcomes following different types of surgical resection in a large sample of patients with AIS/MIA.
Methods: Medical records of patients with lung AIS/MIA who underwent surgery between 2012 and 2017 were retrospectively reviewed. Clinical characteristics, surgical types and complications, recurrence-free survival, and overall survival were investigated.
Results: A total of 1644 patients (422 AIS and 1222 MIA) were included. The overall surgical complication rate was significantly lower in patients receiving wedge resection (1.0%), and was comparable between patients undergoing segmentectomy (3.3%) or lobectomy (5.6%). Grade ≥ 3 complications occurred in 0.1% of patients in the wedge resection group, and in a comparable proportion of patients in the segmentectomy group (1.5%) and the lobectomy group (1.5%). There was no lymph node metastasis. The 5-year recurrence-free survival rate was 100%. The 5-year overall survival rate in the entire cohort was 98.8%, and was comparable among the wedge resection group (98.8%), the segmentectomy group (98.2%), and the lobectomy group (99.4%).
Conclusions: Sublobar resection, especially wedge resection without lymph node dissection, may be the preferred surgical procedure for patients with AIS/MIA. If there are no risk factors, postoperative follow-up intervals may be extended. These implications should be validated in further studies.
Keywords: adenocarcinoma in situ; minimally invasive adenocarcinoma; safety results; surgery; survival.
Copyright © 2020 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.
Comment in
-
Commentary: Surgery for ground-glass nodules: Free lunch or slippery slope?J Thorac Cardiovasc Surg. 2022 Feb;163(2):465-466. doi: 10.1016/j.jtcvs.2020.12.073. Epub 2020 Dec 25. J Thorac Cardiovasc Surg. 2022. PMID: 33500130 No abstract available.
-
Commentary: Sublobar resection for in situ and minimally invasive adenocarcinoma-less is more.J Thorac Cardiovasc Surg. 2022 Feb;163(2):467-468. doi: 10.1016/j.jtcvs.2021.01.005. Epub 2021 Jan 13. J Thorac Cardiovasc Surg. 2022. PMID: 33551073 No abstract available.
-
Commentary: Computed tomography screening for lung cancer at large in China: Early cure or definitive overtreatment?J Thorac Cardiovasc Surg. 2022 Feb;163(2):466-467. doi: 10.1016/j.jtcvs.2021.01.008. Epub 2021 Jan 13. J Thorac Cardiovasc Surg. 2022. PMID: 33563424 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
